ABBV
stock38AbbVie Inc.
Health Care
Snapshot
Biopharmaceutical company with immunology (Skyrizi, Rinvoq), aesthetics, and neuroscience franchises. High-margin, high-yield dividend grower.
Long-Term Total Return
iDecade-scale view, dividends reinvested, vs. the S&P 500.
Growth of $10,000 invested at the start of the period, total return (price + reinvested dividends). Illustrative.
Fundamental Trends
Ten-plus years of the figures that drive long-term value.
10-year fundamental trend charts
Track revenue, earnings, free cash flow, ROIC, share count, and dividends over a decade-plus — a Premium research tool.
$9/mo or $84/yr · cancel anytime
Valuation Context
iValuation context
See P/E, P/FCF, and EV/EBITDA against historical and sector medians with Premium.
$9/mo or $84/yr · cancel anytime
Moat Analysis
iPatent-protected immunology drugs and a deep pipeline provide pricing power, though patent cliffs require continual replenishment.
Next-gen immunology and neuroscience pipeline aim to offset Humira erosion.
Risk Factors
What could impair the long-term thesis.
- Patent cliffs and biosimilar competition
- High leverage
- Drug-pricing policy
Hypothetical Growth
What a past investment would be worth today.
Hypothetical growth calculator
See what an investment made years ago would be worth today, vs. the S&P 500 — a Premium tool.
$9/mo or $84/yr · cancel anytime
Forward Scenario Modeler
Project a starting investment across multi-decade horizons.
Forward scenario modeler
Model conservative, base, and optimistic returns across 10–40 year horizons with Premium.
$9/mo or $84/yr · cancel anytime
Data as of 2025-12-31. Illustrative sample data for research & education — not live market data, and not a recommendation to buy or sell ABBV.